Published in Cancer Weekly, June 8th, 2004
For the first quarter of 2004, the company recorded a net loss of $20.2 million or $0.24 per share compared with $13.1 million or $0.18 per share for the first quarter of 2003. As of March 31, 2004, Xoma held $79.0 million in cash, cash equivalents, and short-term investments, compared with $85.2 million at December 31, 2003.
Total revenues for the first quarter of 2004 were $0.2 million compared with $3.2 million in the first quarter of 2003. The 2003 figure included license fees from several bacterial cell expression technology license arrangements, as well as revenue derived...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly